Phase II Trial of Emricasan in NASH Cirrhosis and Severe Portal Hypertension

April 10-14, 2019; Vienna, Austria
Although this trial did not meet the primary endpoint of decreasing mean hepatic venous pressure gradient in patients with NASH cirrhosis and severe portal hypertension, positive signals were seen that support additional exploration of emricasan in patients with severe portal hypertension.
Format: Microsoft PowerPoint (.ppt)
File Size: 183 KB
Released: April 17, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Educational grant provided by:
Gilead Sciences

Related Content

Audio from Clinical Care Options: Zobair Younossi, MD, discusses the clinical impact of the most important NAFLD/NASH data from EASL 2019 in Vienna.

Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Released: May 2, 2019

April 10-14, 2019; Vienna, Austria: Expert faculty members summarize key viral hepatitis studies from this important annual conference.

Nancy Reau, MD Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Stefan Zeuzem, MD Released: April 30, 2019

Phase II safety and efficacy data with thyroid hormone receptor beta agonist VK2809 vs placebo in NAFLD, from EASL 2019, as reported by Clinical Care Options (CCO).

Released: April 22, 2019

Planned Month 18 interim analysis of phase III REGENERATE study of obeticholic acid vs placebo for NASH from EASL 2019, reported by CCO

Released: April 16, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?